Intraperitoneal anti-PD-L1 increases survival in a novel ovarian cancer model and its in vivo efficacy is influenced by baseline anti-tumor immunity of the host

被引：0
|
作者：
Mony, Jyothi
Zhang, Lixin
Tirodkar, Tejas
Elishaev, Esther
Brozick, Joan
Edwards, Robert P.
Vlad, Anda M.
机构：
[1] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA
[2] Magee Womens Res Inst, Pittsburgh, PA USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷
关键词：
D O I：
10.1158/1557-3265.OVCASYMP14-POSTER-THER-1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
THER-1434
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cimetidine Attenuates Therapeutic Effect of Anti-PD-1 and Anti-PD-L1 and Modulates Tumor Microenvironment in Colon Cancer
    Kuo, Feng-Chi
    Lai, Jerry Cheng-Yen
    Shieh, Hui-Ru
    Liou, Wan-Zu
    Bair, Ming-Jong
    Chen, Yu-Jen
    BIOMEDICINES, 2024, 12 (03)
  • [42] Combination of mesothelin-targeted immune-activating fusion protein and anti-PD-L1 augments antitumor immunity and prolongs survival in murine model of ovarian cancer
    Zeng, Yang
    Li, Binghao
    Liu, Qiuyan
    Reeves, Patrick
    Sluder, Ann
    Gelfand, Jeffrey
    Brauns, Timothy
    Poznansky, Mark
    Chen, Huabiao
    CANCER RESEARCH, 2017, 77
  • [43] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
    Allen, Elizabeth
    Jabouille, Arnaud
    Rivera, Lee B.
    Lodewijckx, Inge
    Missiaen, Rindert
    Steri, Veronica
    Feyen, Kevin
    Tawney, Jaime
    Hanahan, Douglas
    Michael, Iacovos P.
    Bergers, Gabriele
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)
  • [44] PD-1 and IL-10: partners in crime against anti-tumor immunity in ovarian cancer.
    Lamichhane, Purushottam
    Karyampudi, Lavakumar
    Shreeder, Barath
    Knutson, Keith
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [45] Novel mRNA encoding anti-PD-L1 monoclonal antibodies for cancer immunotherapy
    Chung, Ezra
    Bong, Yong Sik
    Chen, Renxiang
    Zhang, Michael
    Long, Steven
    Shen, Dong
    CANCER RESEARCH, 2024, 84 (06)
  • [46] Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy
    Xiang, Yucheng
    Chen, Liqiang
    Liu, Chendong
    Yi, Xiaoli
    Li, Lian
    Huang, Yuan
    SMALL, 2022, 18 (06)
  • [47] Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer
    Fu, Qiang
    Shen, Qian
    Tong, Jin
    Huang, Liu
    Cheng, Yi
    Zhong, Wei
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [48] Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression
    Wang, Shu Shi
    Liu, Ye
    Zhang, Xuan Ting
    Yu, Dong Qiang
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 260 (01): : 63 - 73
  • [49] PD-L1 on the endothelium of micrangium inside tumor: A novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 (TQ-B2450)?
    Ma, L.
    Zhang, C.
    Han, B.
    Chu, T.
    Wang, Q.
    Cheng, Y.
    Li, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S1388 - S1388
  • [50] PD-L1 blockade enhances anti-tumor efficacy of NK cells
    Oyer, Jeremiah L.
    Gitto, Sarah B.
    Altomare, Deborah A.
    Copik, Alicja J.
    ONCOIMMUNOLOGY, 2018, 7 (11):
12345